Titre : Microbiologie industrielle

Microbiologie industrielle : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C5
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Microbiologie industrielle : Questions médicales les plus fréquentes", "headline": "Microbiologie industrielle : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Microbiologie industrielle : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-15", "dateModified": "2025-04-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Microbiologie industrielle" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Biotechnologie", "url": "https://questionsmedicales.fr/mesh/D001709", "about": { "@type": "MedicalCondition", "name": "Biotechnologie", "code": { "@type": "MedicalCode", "code": "D001709", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.897.120" } } }, "about": { "@type": "MedicalCondition", "name": "Microbiologie industrielle", "alternateName": "Industrial Microbiology", "code": { "@type": "MedicalCode", "code": "D007218", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Kyoung-Ho Song", "url": "https://questionsmedicales.fr/author/Kyoung-Ho%20Song", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea." } }, { "@type": "Person", "name": "Eu Suk Kim", "url": "https://questionsmedicales.fr/author/Eu%20Suk%20Kim", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea." } }, { "@type": "Person", "name": "Yee Gyung Kwak", "url": "https://questionsmedicales.fr/author/Yee%20Gyung%20Kwak", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea." } }, { "@type": "Person", "name": "Hong Bin Kim", "url": "https://questionsmedicales.fr/author/Hong%20Bin%20Kim", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.", "datePublished": "2023-11-06", "url": "https://questionsmedicales.fr/article/37929639", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/path.6220" } }, { "@type": "ScholarlyArticle", "name": "Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T", "datePublished": "2023-05-07", "url": "https://questionsmedicales.fr/article/37150813", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/cup.14442" } }, { "@type": "ScholarlyArticle", "name": "A Greater Increase in Complement C5a Receptor 1 Level at Onset and a Smaller Decrease in Immunoglobulin G Level after Recovery in Severer Coronavirus Disease 2019 Patients: A New Analysis of Existing Data with a New Two-Tailed", "datePublished": "2023-08-28", "url": "https://questionsmedicales.fr/article/37759576", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/biology12091176" } }, { "@type": "ScholarlyArticle", "name": "Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.", "datePublished": "2022-07-19", "url": "https://questionsmedicales.fr/article/35868613", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.trim.2022.101672" } }, { "@type": "ScholarlyArticle", "name": "Statement complementing the EFSA Scientific Opinion on application (EFSA-GMO-NL-2015-126) for authorisation of food and feed containing, consisting of and produced from genetically modified soybean MON 87705 × MON 87708 × MON 89788.", "datePublished": "2024-10-28", "url": "https://questionsmedicales.fr/article/39469434", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2903/j.efsa.2024.9061" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Technologie", "item": "https://questionsmedicales.fr/mesh/D013672" }, { "@type": "ListItem", "position": 4, "name": "Biotechnologie", "item": "https://questionsmedicales.fr/mesh/D001709" }, { "@type": "ListItem", "position": 5, "name": "Microbiologie industrielle", "item": "https://questionsmedicales.fr/mesh/D007218" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Microbiologie industrielle - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Microbiologie industrielle", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Microbiologie industrielle", "description": "Comment identifier les micro-organismes en industrie ?\nQuels tests sont utilisés pour le contrôle qualité ?\nComment détecter les contaminants microbiens ?\nQuelles sont les méthodes de détection des pathogènes ?\nComment évaluer la viabilité des micro-organismes ?", "url": "https://questionsmedicales.fr/mesh/D007218?mesh_terms=Complement+C5&page=172#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Microbiologie industrielle", "description": "Quels sont les effets des micro-organismes en industrie ?\nComment les micro-organismes affectent-ils les produits ?\nQuels symptômes indiquent une contamination ?\nQuels sont les signes d'une fermentation indésirable ?\nComment reconnaître une infection microbienne ?", "url": "https://questionsmedicales.fr/mesh/D007218?mesh_terms=Complement+C5&page=172#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Microbiologie industrielle", "description": "Comment prévenir la contamination en production ?\nQuelles sont les bonnes pratiques de fabrication ?\nComment gérer les déchets microbiologiques ?\nQuels équipements sont nécessaires pour la prévention ?\nComment former le personnel à la sécurité microbiologique ?", "url": "https://questionsmedicales.fr/mesh/D007218?mesh_terms=Complement+C5&page=172#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Microbiologie industrielle", "description": "Quels traitements sont utilisés contre les contaminations ?\nComment prévenir les infections en milieu industriel ?\nQuels sont les traitements pour les produits contaminés ?\nComment traiter les infections causées par des pathogènes ?\nQuelles méthodes de biocontrôle existent ?", "url": "https://questionsmedicales.fr/mesh/D007218?mesh_terms=Complement+C5&page=172#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Microbiologie industrielle", "description": "Quelles complications peuvent survenir en microbiologie industrielle ?\nComment les infections peuvent-elles affecter la production ?\nQuels sont les risques de résistance aux antibiotiques ?\nComment les contaminations affectent-elles la sécurité alimentaire ?\nQuelles sont les conséquences d'une mauvaise gestion des déchets ?", "url": "https://questionsmedicales.fr/mesh/D007218?mesh_terms=Complement+C5&page=172#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Microbiologie industrielle", "description": "Quels facteurs augmentent le risque de contamination ?\nComment le personnel peut-il être un facteur de risque ?\nQuels environnements favorisent la prolifération microbienne ?\nComment les équipements mal entretenus augmentent-ils les risques ?\nQuels produits sont plus susceptibles d'être contaminés ?", "url": "https://questionsmedicales.fr/mesh/D007218?mesh_terms=Complement+C5&page=172#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les micro-organismes en industrie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des techniques comme la culture, la PCR et le séquençage génétique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le contrôle qualité ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests microbiologiques, chimiques et physiques sont effectués pour garantir la qualité." } }, { "@type": "Question", "name": "Comment détecter les contaminants microbiens ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des méthodes de détection rapide comme les tests ELISA et les milieux sélectifs." } }, { "@type": "Question", "name": "Quelles sont les méthodes de détection des pathogènes ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent la PCR, les cultures et les tests immunologiques spécifiques." } }, { "@type": "Question", "name": "Comment évaluer la viabilité des micro-organismes ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des méthodes de coloration, de culture et des tests de respiration." } }, { "@type": "Question", "name": "Quels sont les effets des micro-organismes en industrie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent provoquer des fermentations, des dégradations ou des contaminations." } }, { "@type": "Question", "name": "Comment les micro-organismes affectent-ils les produits ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent altérer le goût, l'odeur et la texture des produits alimentaires." } }, { "@type": "Question", "name": "Quels symptômes indiquent une contamination ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des changements de couleur, d'odeur ou de texture peuvent signaler une contamination." } }, { "@type": "Question", "name": "Quels sont les signes d'une fermentation indésirable ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des bulles, des odeurs désagréables et des changements de pH peuvent apparaître." } }, { "@type": "Question", "name": "Comment reconnaître une infection microbienne ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fièvre, la fatigue et des douleurs peuvent indiquer une infection." } }, { "@type": "Question", "name": "Comment prévenir la contamination en production ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des pratiques d'hygiène rigoureuses et des contrôles réguliers sont essentiels." } }, { "@type": "Question", "name": "Quelles sont les bonnes pratiques de fabrication ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Suivre les normes HACCP et former le personnel sont des pratiques clés." } }, { "@type": "Question", "name": "Comment gérer les déchets microbiologiques ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les déchets doivent être stérilisés et éliminés selon les réglementations en vigueur." } }, { "@type": "Question", "name": "Quels équipements sont nécessaires pour la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des équipements de protection individuelle et des systèmes de filtration sont recommandés." } }, { "@type": "Question", "name": "Comment former le personnel à la sécurité microbiologique ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des formations régulières sur les risques microbiologiques et les protocoles de sécurité sont cruciales." } }, { "@type": "Question", "name": "Quels traitements sont utilisés contre les contaminations ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des désinfectants, des antibiotiques et des méthodes de pasteurisation." } }, { "@type": "Question", "name": "Comment prévenir les infections en milieu industriel ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des protocoles d'hygiène stricts et des formations sont essentiels pour prévenir les infections." } }, { "@type": "Question", "name": "Quels sont les traitements pour les produits contaminés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La décontamination, la pasteurisation ou l'élimination des produits peuvent être nécessaires." } }, { "@type": "Question", "name": "Comment traiter les infections causées par des pathogènes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des antibiotiques spécifiques et des traitements symptomatiques sont souvent utilisés." } }, { "@type": "Question", "name": "Quelles méthodes de biocontrôle existent ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation de micro-organismes bénéfiques pour inhiber les pathogènes est une méthode efficace." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir en microbiologie industrielle ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des contaminations croisées, des pertes de production et des problèmes de santé publique peuvent survenir." } }, { "@type": "Question", "name": "Comment les infections peuvent-elles affecter la production ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les infections peuvent entraîner des arrêts de production et des pertes économiques significatives." } }, { "@type": "Question", "name": "Quels sont les risques de résistance aux antibiotiques ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation excessive d'antibiotiques peut conduire à des souches résistantes, compliquant les traitements." } }, { "@type": "Question", "name": "Comment les contaminations affectent-elles la sécurité alimentaire ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent entraîner des rappels de produits et des risques pour la santé des consommateurs." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une mauvaise gestion des déchets ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise gestion peut entraîner des contaminations environnementales et des risques sanitaires." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de contamination ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des conditions de stockage inadéquates et un manque d'hygiène augmentent le risque." } }, { "@type": "Question", "name": "Comment le personnel peut-il être un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Un personnel mal formé ou négligeant les protocoles peut introduire des contaminants." } }, { "@type": "Question", "name": "Quels environnements favorisent la prolifération microbienne ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les environnements humides et chauds sont propices à la prolifération des micro-organismes." } }, { "@type": "Question", "name": "Comment les équipements mal entretenus augmentent-ils les risques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des équipements non stérilisés ou mal entretenus peuvent devenir des sources de contamination." } }, { "@type": "Question", "name": "Quels produits sont plus susceptibles d'être contaminés ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les produits alimentaires, les cosmétiques et les médicaments sont souvent à risque." } } ] } ] }

Sources (1718 au total)

Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T

Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However... BP-irAE (n = 8) and de novo BP control (n = 8) biopsy samples were subjected to gene expression profiling using the NanoString® Technologies nCounter PanCancer Immune Profiling Panel. Multiplex immuno... Compared with de novo BP controls, BP-irAE samples exhibited upregulation of 30 mRNA transcripts (p < 0.025), including toll-like receptor 4 (TLR4) and genes associated with complement activation, and... BP-irAE exhibited activation of the TLR4/complement-driven classical innate immune response pathway, with dermal T...

Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.

It is controversial whether all donor-specific antibodies (DSA) detected by the solid-phase single antigen bead (SAB) assay negatively affect kidney transplantation outcomes. The study aimed to evalua... From the historical cohort of living donor recipients transplanted between 2014 and 2018 at our center (n = 82), 55 patients met the inclusion criteria, namely: these patients were > 18 years old with... In the studied cohort, DSA-positive, NDSA reactive, and anti-HLA negative recipients constituted 33%, 36%, and 31% of 55 patients, respectively. Non-routinely considered pre-transplant HLA-DQ, -DP, an... Our 3-year follow-up of patients with low pre-transplant DSA found no association with a deterioration in graft function and worse graft survival. Furthermore, we did not observe an increase in AMR in...

Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.

Diffuse intrinsic pontine glioma (DIPG) and paediatric high-grade glioma (pHGG) are aggressive glial tumours, for which conventional treatment modalities fall short. Dendritic cell (DC)-based immunoth... 10 paediatric patients with newly diagnosed or pretreated HGG or DIPG were treated according to the trial protocol. The trial protocol consists of leukapheresis of mononuclear cells, the manufacturing... The ethics committee of the Antwerp University Hospital and the University of Antwerp granted ethics approval. Results of the clinical trial will be shared through publication in a peer-reviewed journ... NCT04911621....

Complement component 5a receptor 1 and leukotriene B4 receptor 1 regulate neutrophil extracellular trap (NET) formation through Rap1a/B-Raf/ERK signaling pathway and their deficiency in term low birth weight newborns leads to deficient NETosis.

Neutrophil extracellular traps (NETs) being one of the predominant activities of neutrophils has become its key defense mechanism owing to its extensive role in inflammation and infection. However, th... The validation of the transcriptomic data for C5aR1 and LTB4R1 was done using quantitative real time PCR. Pharmacological inhibition of C5aR1 and LTB4R1 using W-54011 and LY223982 on neutrophils of ad... The expression of C5aR1 and LTB4R1, extracellular DNA, ROS and NET associated proteins (NE, CitH3, PAD4 and MPO) was notably increased upon NET induction in healthy adults and normal birth weight (NBW... The C5aR1 and LTB4R1 signaling via Rap1a/B-Raf/ERK axis acts as a signal-relay mechanism to regulate NET formation in neutrophils. Further, C5aR1 and LTB4R1 signaling cascade along with NET-associated...

The Use of Fissios App© as a Complement to a Face-to-Face Respiratory Physiotherapy Program versus an Attendance-Only Face-to-Face Physiotherapy Program in Patients Scheduled for Thoracic Surgical Procedures Reduces the Risk of Developing Postoperative Pulmonary Complications-A Quasi-Experimental Study.

Postoperative pulmonary complications (PPCs) increase the hospital length of stay (LOS) and the cost of healthcare associated with surgical procedures. Strategies to reduce PPCs begin before surgery a...